Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice-Reference-Cited by-同舟云学术

Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice

Published:2020-05-01 Issue:5 Volume:156 Page:570
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Wensink Debby¹,Wagenmakers Margreet A. E. M.¹,Barman-Aksözen Jasmin²,Friesema Edith C. H.¹,Wilson J. H. Paul¹,van Rosmalen Joost³,Langendonk Janneke G.¹

Affiliation:

1. Porphyria Center Rotterdam, Center for Lysosomal and Metabolic Disease, Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, the Netherlands

2. Institute of Laboratory Medicine, Municipal Hospital Triemli, Zürich, Switzerland

3. Department of Biostatistics, Erasmus MC, University Medical Center, Rotterdam, the Netherlands

Publisher

American Medical Association (AMA)

Subject

Dermatology

Link

https://jamanetwork.com/journals/jamadermatology/articlepdf/2762869/jamadermatology_wensink_2020_br_200002.pdf

Reference13 articles.

1. Evidence and conjecture about mechanisms of cutaneous disease in photodermatology.;Porter;Exp Dermatol,2014

2. Erythropoietic protoporphyria.;Lecha;Orphanet J Rare Dis,2009

3. Porphyrin and heme metabolism and the porphyrias.;Bonkovsky;Compr Physiol,2013

4. Erythropoietic protoporphyria in the UK: clinical features and effect on quality of life.;Holme;Br J Dermatol,2006

5. Erythropoietic protoporphyria.;Todd;Br J Dermatol,1994

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Erythropoietic protoporphyrias: updates and advances;Trends in Molecular Medicine;2024-09

2. Erythropoietic protoporphyrias: Pathogenesis, diagnosis and management;Liver International;2024-07-16

3. Quality of life in children with erythropoietic protoporphyria: a case–control study;The Journal of Dermatology;2024-06-26

4. Afamelanotide for Treatment of the Protoporphyrias: Impact on Quality of Life and Laboratory Parameters in a US Cohort;Life;2024-05-28

5. Fair Funding Decisions: Consistency of the Time Horizons Used in the Calculation of Quality-Adjusted Life Years for Therapies for Very Rare Diseases by the National Institute for Health and Care Excellence in England;International Journal of Environmental Research and Public Health;2024-05-13